<p><em>综合平台连接了超过 250,000 名患者、40,000 名临床医生和 90 多家生物制药合作伙伴——为精准医学的执行和结果创造了一个真实世界的网络</em></p>
<p>, /PRNewswire/ -- Nexus Precision Health（&#34;Nexus&#34;），一家精准医学技术公司，今天宣布已收购 Leal Health，这是一款基于人工智能的患者决策支持平台。交易条款未披露。</p>
<p>此次收购创建了一个集成平台，旨在将癌症、罕见遗传疾病和心理健康状况的患者与合适的治疗、临床试验或扩展接入途径进行匹配——以规模化的方式。Leal Health 带来了专利的 GEN-AI 引擎，能够生成个性化的治疗计划，并与 40,000 多名临床医生、90 多家生物制药合作伙伴以及与美国五大健康保险公司中的两家进行互动的实时生态系统相结合。</p>
<p>尽管人工智能技术取得了进展，但临床采用仍因缺乏临床医生信任、现实世界验证不足和报销不明确而停滞不前。Nexus–Leal 通过将透明的生物推理嵌入临床工作流程中，生成使用过程中的真实世界证据，并与基于价值的护理模型对齐，来解决这些障碍。Leal Health 的能力使先进的 GEN-AI 技术能够快速且低成本地收集真实世界数据，生成治疗计划，教育医生和患者，并创建无痛的测试订购途径——帮助患者更快地获得更好的治疗，赋能医生以可操作的情报，并减少医疗系统中的浪费。</p>
<p>领导者观点</p>
<p>&#34;这是一个建立类别的时刻，使精准医学能够在规模上执行，&#34; <strong>Nexus Precision Health 执行董事长 Ascher Shmulewitz</strong> 表示。&#34;我们可以共同将精准医学从承诺转变为可重复的系统。&#34;</p>
<p>&#34;我们的目标很简单：人工智能技术不应被孤立；在现实世界中实施先进的精准医学技术——让每位需要它的患者都能受益。&#34;</p>
<p>— <strong>Nexus Precision Health 首席执行官 Asher Nathan</strong></p>
<p>&#34;在这个阶段，基本面是罕见的：一个可操作的可扩展基础，一个经过验证的网络和已建立的单位经济，使我们能够在不从头开始重建的情况下，捕获 2500 亿美元市场的显著份额。这是投资者在如此早期阶段很少看到的使命与利润的结合。&#34;</p>
<p><em>—</em> <strong>Nexus Precision Health 董事会成员及投资者 Everett Kamin</strong> <em>&#34;</em></p>
<p>&#34;我创立 Leal Health 是因为我相信每位患者都应获得所有选择的公正视角。通过加入 Nexus，我们可以将使命扩展到罕见遗传疾病和心理健康领域——在这些领域，患者和家庭花费数年时间寻找答案。&#34;</p>
<p>— <strong>Leal Health 首席执行官 Tzvia Bader</strong>，她将加入 Nexus 的执行领导团队。</p>
<p>技术与人工智能合作伙伴：[email protected]</p>
<p>投资者：[email protected]</p>
<p>关于 Nexus Precision Health</p>
<p>Nexus Precision Health 加速癌症、罕见遗传疾病和心理健康状况的规模化治疗——连接患者、临床医生、支付方和生物制药，以帮助每位患者在几分钟内找到最佳可用选项。</p>
<p>关于 Leal Health</p>
<p>Leal Health 是一款基于人工智能的决策支持平台，拥有专利技术，提供最准确的治疗选项数据，已与 90 多家生物制药公司合作，促成超过 300 万次治疗匹配。https://leal.health</p>
<p>前瞻性声明：本新闻稿包含关于收购预期收益、计划扩展和平台增长的前瞻性声明。实际结果可能因整合、监管和市场因素等风险而大幅不同。</p>
<p>媒体联系人：</p>
<p>Asher Nathan，首席执行官</p>
<p>Nexus Precision Health</p>
<p>774 828-0027（美国）</p>
<p>+972 54 559-1441（以色列）</p>
<p>[email protected]</p>
<p>来源 Nexus Precision Health</p>
<p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwMjI1Jk5ld3NJdGVtSWQ9UEg5NTg3MSZUcmFuc21pc3Npb25fSWQ9MjAyNjAyMjUxMzAxUFJfTkVXU19VU1BSX19fX19QSDk1ODcx?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwMjI1Jk5ld3NJdGVtSWQ9UEg5NTg3MSZUcmFuc21pc3Npb25fSWQ9MjAyNjAyMjUxMzAxUFJfTkVXU19VU1BSX19fX19QSDk1ODcx"/></p>

<p>Nexus Precision Health 已收购 Leal Health，这是一款基于人工智能的患者决策支持平台，旨在增强精准医疗。该集成平台连接了超过 250,000 名患者、40,000 名临床医生和 90 家生物制药合作伙伴，旨在将患者与合适的治疗方案和临床试验匹配。此次收购解决了人工智能在医疗保健中临床应用的障碍，通过将生物推理嵌入工作流程并生成真实世界证据。领导层强调了有效扩展精准医疗的潜力，目标市场为 2500 亿美元</p>

<p><em>Combined platform connects 250,000+ patients, 40,000+ clinicians, and 90+ biopharma partners—creating a real-world network for precision medicine execution and outcomes</em></p>
<div class="lb-trans"><p><em>综合平台连接了超过 250,000 名患者、40,000 名临床医生和 90 多家生物制药合作伙伴——为精准医学的执行和结果创造了一个真实世界的网络</em></p>
</div><p>, /PRNewswire/ -- Nexus Precision Health (&#34;Nexus&#34;), a precision medicine technology company, today announced it has acquired Leal Health, the AI-powered patient decision-support platform. Terms of the transaction were not disclosed.</p>
<div class="lb-trans"><p>, /PRNewswire/ -- Nexus Precision Health（&#34;Nexus&#34;），一家精准医学技术公司，今天宣布已收购 Leal Health，这是一款基于人工智能的患者决策支持平台。交易条款未披露。</p>
</div><p>The acquisition creates an integrated platform designed to match patients with cancer, rare genetic diseases, and mental health conditions to the right therapy, clinical trial, or expanded access pathway—at scale. Leal Health brings a patented GEN- AI engine that generates personalized treatment plans, along with a live ecosystem of 40,000+ clinicians, 90+ biopharma partners, and engagements with two of the five largest U.S. health insurers.</p>
<div class="lb-trans"><p>此次收购创建了一个集成平台，旨在将癌症、罕见遗传疾病和心理健康状况的患者与合适的治疗、临床试验或扩展接入途径进行匹配——以规模化的方式。Leal Health 带来了专利的 GEN-AI 引擎，能够生成个性化的治疗计划，并与 40,000 多名临床医生、90 多家生物制药合作伙伴以及与美国五大健康保险公司中的两家进行互动的实时生态系统相结合。</p>
</div><p>Despite advances in AI technology, clinical adoption remains stalled by a lack of clinician trust, insufficient real-world validation, and unclear reimbursement. Nexus–Leal addresses these barriers by embedding transparent biological reasoning into clinical workflows, generating real-world evidence as a byproduct of use, and aligning with value-based care models. Leal Health's capabilities enable advanced GEN- AI technologies to quickly and inexpensively amass real-world data, generate a treatment plan, educate both physicians and patients, and create a painless pathway to ordering the right test—helping patients access better treatments sooner, empowering doctors with actionable intelligence, and reducing waste across healthcare systems.</p>
<div class="lb-trans"><p>尽管人工智能技术取得了进展，但临床采用仍因缺乏临床医生信任、现实世界验证不足和报销不明确而停滞不前。Nexus–Leal 通过将透明的生物推理嵌入临床工作流程中，生成使用过程中的真实世界证据，并与基于价值的护理模型对齐，来解决这些障碍。Leal Health 的能力使先进的 GEN-AI 技术能够快速且低成本地收集真实世界数据，生成治疗计划，教育医生和患者，并创建无痛的测试订购途径——帮助患者更快地获得更好的治疗，赋能医生以可操作的情报，并减少医疗系统中的浪费。</p>
</div><p>Leadership Perspective</p>
<div class="lb-trans"><p>领导者观点</p>
</div><p>&#34;This is a category-building moment that makes precision medicine executable at scale,&#34; said <strong>Ascher Shmulewitz, Executive Chairman of Nexus Precision Health</strong>. &#34;Together, we can turn precision medicine from a promise into a repeatable system.&#34;</p>
<div class="lb-trans"><p>&#34;这是一个建立类别的时刻，使精准医学能够在规模上执行，&#34; <strong>Nexus Precision Health 执行董事长 Ascher Shmulewitz</strong> 表示。&#34;我们可以共同将精准医学从承诺转变为可重复的系统。&#34;</p>
</div><p>&#34;Our goal is simple: AI tech should not be siloed; implement advanced precision medicine technologies in the real world—so every patient who needs them can benefit.&#34;</p>
<div class="lb-trans"><p>&#34;我们的目标很简单：人工智能技术不应被孤立；在现实世界中实施先进的精准医学技术——让每位需要它的患者都能受益。&#34;</p>
</div><p>— <strong>Asher Nathan, CEO of Nexus Precision Health</strong></p>
<div class="lb-trans"><p>— <strong>Nexus Precision Health 首席执行官 Asher Nathan</strong></p>
</div><p>&#34;The fundamentals are rare at this stage: an operationally scalable base, a validated network and established unit economics that enable us to capture significant share of a $250 billion market without rebuilding from scratch. This is a combination of mission and margin that investors rarely see this early.&#34;</p>
<div class="lb-trans"><p>&#34;在这个阶段，基本面是罕见的：一个可操作的可扩展基础，一个经过验证的网络和已建立的单位经济，使我们能够在不从头开始重建的情况下，捕获 2500 亿美元市场的显著份额。这是投资者在如此早期阶段很少看到的使命与利润的结合。&#34;</p>
</div><p><em>—</em> <strong>Everett Kamin, Board and Investor, Nexus Precision Health</strong> <em>&#34;</em></p>
<div class="lb-trans"><p><em>—</em> <strong>Nexus Precision Health 董事会成员及投资者 Everett Kamin</strong> <em>&#34;</em></p>
</div><p>&#34;I founded Leal Health because I believe every patient deserves an unbiased view of all their options. By joining Nexus, we can expand the mission into rare genetic diseases and mental health—where patients and families spend years searching for answers.&#34;</p>
<div class="lb-trans"><p>&#34;我创立 Leal Health 是因为我相信每位患者都应获得所有选择的公正视角。通过加入 Nexus，我们可以将使命扩展到罕见遗传疾病和心理健康领域——在这些领域，患者和家庭花费数年时间寻找答案。&#34;</p>
</div><p>— <strong>Tzvia Bader, CEO of Leal Health</strong>, who joins the Nexus executive leadership team.</p>
<div class="lb-trans"><p>— <strong>Leal Health 首席执行官 Tzvia Bader</strong>，她将加入 Nexus 的执行领导团队。</p>
</div><p>Technology &amp; AI Partners: [email protected]</p>
<div class="lb-trans"><p>技术与人工智能合作伙伴：[email protected]</p>
</div><p>Investors: [email protected]</p>
<div class="lb-trans"><p>投资者：[email protected]</p>
</div><p>About Nexus Precision Health</p>
<div class="lb-trans"><p>关于 Nexus Precision Health</p>
</div><p>Nexus Precision Health accelerates the treatment of cancer, rare genetic diseases, and mental health conditions at scale—connecting patients, clinicians, payers, and biopharma to help every patient reach the best available option in minutes.</p>
<div class="lb-trans"><p>Nexus Precision Health 加速癌症、罕见遗传疾病和心理健康状况的规模化治疗——连接患者、临床医生、支付方和生物制药，以帮助每位患者在几分钟内找到最佳可用选项。</p>
</div><p>About Leal Health</p>
<div class="lb-trans"><p>关于 Leal Health</p>
</div><p>Leal Health is an AI-powered decision-support platform with patented technology that delivers the most accurate treatment-option data available, having facilitated over 3 million treatment matches in partnership with 90+ biopharma companies. https://leal.health</p>
<div class="lb-trans"><p>Leal Health 是一款基于人工智能的决策支持平台，拥有专利技术，提供最准确的治疗选项数据，已与 90 多家生物制药公司合作，促成超过 300 万次治疗匹配。https://leal.health</p>
</div><p>Forward-Looking Statements: This press release contains forward-looking statements regarding expected benefits of the acquisition, planned expansion, and platform growth. Actual results may differ materially due to risks including integration, regulatory, and market factors.</p>
<div class="lb-trans"><p>前瞻性声明：本新闻稿包含关于收购预期收益、计划扩展和平台增长的前瞻性声明。实际结果可能因整合、监管和市场因素等风险而大幅不同。</p>
</div><p>Media Contact:</p>
<div class="lb-trans"><p>媒体联系人：</p>
</div><p>Asher Nathan, CEO</p>
<div class="lb-trans"><p>Asher Nathan，首席执行官</p>
</div><p>Nexus Precision Health</p>
<div class="lb-trans"><p>Nexus Precision Health</p>
</div><p>774 828-0027 (US)</p>
<div class="lb-trans"><p>774 828-0027（美国）</p>
</div><p>+972 54 559-1441 (ISRAEL)</p>
<div class="lb-trans"><p>+972 54 559-1441（以色列）</p>
</div><p>[email protected]</p>
<div class="lb-trans"><p>[email protected]</p>
</div><p>SOURCE Nexus Precision Health</p>
<div class="lb-trans"><p>来源 Nexus Precision Health</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwMjI1Jk5ld3NJdGVtSWQ9UEg5NTg3MSZUcmFuc21pc3Npb25fSWQ9MjAyNjAyMjUxMzAxUFJfTkVXU19VU1BSX19fX19QSDk1ODcx" alt="" original-src="https://rt.prnewswire.com/rt.gif?NewsItemId=PH95871&amp;Transmission_Id=202602251301PR_NEWS_USPR_____PH95871&amp;DateId=20260225"/></p>

Nexus Precision Health 收购 Leal Health 以加速大规模的精准医疗